David E. Cobrinik, MD, PhD

Professor of Research Ophthalmology and Cancer Biology

Image of David E. Cobrinik, MD, PhD
Is this your profile? Click to edit

Overview

Our research seeks to improve understanding of retinal development and its relationship to retinal diseases. This goal stems from my long interest in a childhood retinal tumor called retinoblastoma, a cancer that develops in response to inactivation of the RB1 tumor suppressor gene and loss of functional pRB protein. One of our goals is to understand why cells of the retina but not other tissues routinely form cancers in response to pRB loss, and to use this knowledge to develop more effective therapies for retinoblastoma and other RB1-mutant cancers. We recently found that retinoblastomas arise from cone photoreceptor precursors, and that cone precursor-specific proliferation-related signaling pathways collaborate with pRB loss to enable tumorigenesis. This finding suggests that cone precursors signaling pathways can be targeted to suppress retinoblastoma development. Current studies aim to 1) define developmental signaling pathways that sensitize retinal cells to Rb loss, 2) define the step-by-step events through which Rb loss converts normal retinal cells to malignant retinoblastomas, and 3) target novel vulnerabilities in the pRB-deficient cone precursor circuitry.

With our colleagues at the CHLA Vision Center we also model retinal development and diseases using human pluripotent stem cells. We can produce normal-appearing developing retinas in vitro, opening the door to previously unimagined vision research opportunities. Current efforts aim to define similarities and differences between human retina produced in vitro and in vivo, and to thereby improve the verisimilitude of the in vitro retinal development model.

Awards

  • International Society for Genetic Eye Diseases and Retinoblastoma: The Ellsworth Lecture, 2023
  • James S. McDonnell Foundation: James S. McDonnell Scholar, 1996
     – 1999
  • Susan G. Komen Breast Cancer Foundation: Susan G. Komen Foundation Postdoctoral Fellow, 1992
     – 1995
  • American Cancer Society: ACS Postdoctoral Fellow, 1989
     – 1992
  • American Cancer Society: Joseph S. Silber Pre-doctoral Fellow, 1983
  • Amherst College: Oscar E. Schotté Award for Biological Research, 1982

Education and Training

  • Amherst College, Amherst, MA — BA — 05/1982 — Biology
  • Case Western Reserve University, Cleveland, OH — MD, PhD — 05/1989 — Biochemistry, Medicine
  • Whitehead Institute, Cambridge, MA — Postdoctoral — 1995 — Cancer Biology

Publications

  • Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol. 2006 Sep; 124(9):1269-75.. View in PubMed
  • Pocket proteins and cell cycle control. Oncogene. 2005 Apr 18; 24(17):2796-809.. View in PubMed
  • The cyclin-dependent kinase inhibitor p57(Kip2) mediates proliferative actions of PTHrP in chondrocytes. J Clin Invest. 2004 May; 113(9):1334-43.. View in PubMed
  • Regulation of PML-dependent transcriptional repression by pRB and low penetrance pRB mutants. Oncogene. 2002 Aug 15; 21(36):5557-65.. View in PubMed
  • FGF signaling targets the pRb-related p107 and p130 proteins to induce chondrocyte growth arrest. J Cell Biol. 2002 Aug 19; 158(4):741-50.. View in PubMed
  • p107 and p130 Coordinately regulate proliferation, Cbfa1 expression, and hypertrophic differentiation during endochondral bone development. Dev Biol. 2002 Jul 15; 247(2):271-85.. View in PubMed
  • Rho regulates p21(CIP1), cyclin D1, and checkpoint control in mammary epithelial cells. Oncogene. 2002 Feb 28; 21(10):1590-9.. View in PubMed
  • Complementary and alternative medicine: the role of the cancer center. J Clin Oncol. 2001 Sep 15; 19(18 Suppl):55S-60S.. View in PubMed
  • Cdk2-dependent phosphorylation and functional inactivation of the pRB-related p130 protein in pRB(-), p16INK4A(+) tumor cells. J Biol Chem. 2000 Sep 29; 275(39):30317-25.. View in PubMed
  • Growth factor-dependent induction of p21(CIP1) by the green tea polyphenol, epigallocatechin gallate. Cancer Lett. 2000 Jun 30; 154(2):151-61.. View in PubMed